Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson’s Disease

Overview

This study aims to describe hallucinations prevalence in a sample of patients affected by Parkinson's disease and consulting in an outpatient facility.

An unique one hour interview will be offered to volunteers patients. Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.

The study hypothesis is that hallucinations prevalence in Parkinson's disease is underestimated and is higher than usually described in the scientific literature when all hallucinations modalities and minor hallucinatory phenomenons are searched for.

Full Title of Study: “Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson’s Disease”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: April 25, 2018

Interventions

  • Other: Assessment of hallucinations in Parkinson’s disease
    • Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.

Arms, Groups and Cohorts

  • Patients affected by Parkinson’s disease
    • Outpatients affected by Parkinson’s Disease consulting in neurology can be included if volunteer

Clinical Trial Outcome Measures

Primary Measures

  • Hallucinations Prevalence
    • Time Frame: 1 hour
    • Semi-structured questionnaire precisely describing hallucinations of all modalities and their characteristics, as well as minor hallucinations and delusions. Binary Yes/No possible answers. Unique 1 hour interview to assess semi-structured questionnaire for primary outcome measurement, and psychometric scales.

Participating in This Clinical Trial

Inclusion Criteria

  • Age ≥ 18 years-old
  • Absence of opposition from the patient himself/herself or his/her legal representant for his/her participation to the study
  • Patient without superior age limit with a diagnosis of Parkinson's disease made according to the UKPDSBB criteria (UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria)
  • Outpatient consulting in neurology at the Charpennes'hospital

Exclusion Criteria

  • Opposition to the study
  • Deafness or blindness which could compromise the interview

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hospices Civils de Lyon
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jing XIE, MD, Principal Investigator, Hôpital des Charpennes. Centre de Recherche Clinique – vieillissement, cerveau, fragilité

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.